Trial Profile
A Phase 2 Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms Codex Study
- Sponsors Anchiano Therapeutics
- 15 Nov 2019 Results presented an Anchiano Therapeutics media release.
- 15 Nov 2019 Status changed from recruiting to discontinued according to an Anchiano Therapeutics media release.
- 23 Sep 2019 According to an Anchiano Therapeutics media release, the company is estimating that the data collection and interim analysis will be completed by the first quarter of 2020.